Femasys Inc. (FEMY) Investor Relations Documents
Femasys Inc. (FEMY) investor relations documents from the company's IR site: 1 presentation, 21 press releases; latest deck 2026-05-13. Read in-app with summaries. First-party data.
Download PDF file, (opens in new window) — Femasys (NASDAQ: FEMY) is a biomedical company developing in-office women’s health solutions, led by its FemaSeed fertility treatment for intratubal insemination.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-19 | Press release | Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® |
| 2026-08-14 | Press release | Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update |
| 2026-08-12 | Press release | Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents |
| 2026-08-07 | Press release | Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million |
| 2026-06-24 | Press release | Femasys Regains Compliance with Nasdaq Listing Requirements |
| 2026-05-13 | Presentation | Download PDF file, (opens in new window) |
| 2026-05-13 | Press release | Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter |
| 2026-05-08 | Press release | Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update |
| 2026-05-05 | Press release | Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete |
| 2026-04-22 | Press release | Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 |
| 2026-04-16 | Press release | Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio |
| 2026-04-01 | Press release | Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth |
| 2026-03-31 | Press release | Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update |
| 2026-03-18 | Press release | Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors |
| 2026-03-10 | Press release | Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment |
| 2026-02-27 | Press release | Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-26 | Press release | Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access |
| 2026-02-23 | Press release | Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination |
| 2026-02-03 | Press release | Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products |
| 2026-01-14 | Press release | Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement |
| 2026-01-13 | Press release | Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care |
| 2024-11-12 | Press release | Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update |
FEMY overview · FEMY earnings · FEMY financials · FEMY KPIs · FEMY ownership · FEMY peers · FEMY filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.